PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9259410-4	1997	PC-6/SN2-5 cells were resistant to SN-38 (32-fold) and SK&F 104864 (topotecan; 14-fold), but barely resistant to CPT-11 (3-fold) and DX-8951f (2-fold).	Topotecan	72-81	proprotein convertase subtilisin/kexin type 5	Homo sapiens	0-4	
9259410-6	1997	Determination of the cellular drug concentration by either flow cytometric analysis or the high-performance liquid chromatography method confirmed that the cellular accumulation of SN-38 and topotecan was significantly reduced in PC-6/SN2-5 cells, whereas that of DX-8951f was only slightly reduced.	Topotecan	191-200	proprotein convertase subtilisin/kexin type 5	Homo sapiens	230-234	
15735043-6	2005	The topotecan transport study was done using the plasma membrane vesicles of PC-6/SN2-5H cells.	Topotecan	4-13	proprotein convertase subtilisin/kexin type 5	Homo sapiens	77-81	
14618629-7	2004	Compared to the parental PC-6 cells, PC-6/SN2-5H2 cells were 141-, 173- and 57.2-fold resistant to topotecan, SN-38 and mitoxantrone, respectively.	Topotecan	99-108	proprotein convertase subtilisin/kexin type 5	Homo sapiens	37-41	
14618629-9	2004	Furthermore, novobiocin increased the intracellular topotecan accumulation in these cells and inhibited the topotecan transport into the membrane vesicles of PC-6/SN2-5H2 cells.	Topotecan	108-117	proprotein convertase subtilisin/kexin type 5	Homo sapiens	158-162